Abstract:585 Background: Pathologic complete response (pCR) is a valuable metric for predicting survival following neoadjuvant therapy (NAT) in breast cancer; however, blood-based biomarkers may refine the prediction of treatment outcomes and inform follow-up treatment decisions. Orphan non-coding RNAs (oncRNAs) are a novel category of small RNAs that are present in tumors and largely absent in healthy tissue. Here, we explore the feasibility of a tumor-naive oncRNA-based liquid biopsy assay for predicting distant recurrence-free survival (DRFS) in breast cancer patients using a standard blood draw. Methods: Our cohort included 538 high-risk breast cancer patients from the multicenter I-SPY2 trial having serum available after NAT and before surgery (timepoint T3). Of the 538 patients (mean age: 48.8 ± 10.3), 191 (36%) achieved pCR. We isolated small RNA from 0.8 mL of patient serum and sequenced it at an average depth of 50 million 100-bp single-end reads. We used our catalog of tumor-derived oncRNAs, discovered in The Cancer Genome Atlas, to develop an AI model for predicting tumor burden based on tumor size. Our AI model was trained on oncRNA profiles from an independent cohort of 719 serum samples collected at diagnosis from individuals with cancer. We assessed tumor burden by oncRNA in the I-SPY2 cohort at T3 and associated this measure with DRFS using robust cutpoints established for each of the two pCR groups: high- ( n=70) and low-burden ( n=468) cutpoints were verified through cross-validation and almost all folds converged on a single value, which we used in our analysis. Results: The continuous oncRNA-derived tumor burden at T3 had a hazards ratio (HR) of 2.4 (95% CI: 1.1–5.1) for predicting DRFS. This measure remained significant in multivariate Cox models that included pCR (HR = 2.7 [1.3–5.6]) or residual cancer burden (RCB II/III versus 0/I; HR = 3.4 [1.6–7.1]). Patients with pCR had a 3-year DRFS of 94%; patients with pCR having low ( n=180) versus high ( n=11) oncRNA burden resulted in 95% and 73% 3-year DRFS, respectively (HR = 7.4 [2.3–24]). Those without pCR had a 3-year DRFS of 78% and stratification by oncRNA burden resulted in 85% and 71% 3-year DRFS for the low ( n=288) and high ( n=59) burden groups, respectively (HR=2.4 [1.5–3.9]). Importantly, we saw no restricted mean survival time difference (RMST) at 3 years between those with and without pCR among the high oncRNA burden group (0.1-month difference, p=0.97). Conclusions: We demonstrate the utility of a tumor-naive, oncRNA-derived tumor burden AI model as a predictive measure of treatment outcome and as a prognostic biomarker that can be used in addition to pCR to further stratify patients as low or high risk of recurrence. Integration of our oncRNA assay with existing biomarkers and clinicopathologic variables, has the potential to add value for predicting outcomes and prioritizing patients that would benefit from additional care.

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy

RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy

15P A Novel RNA Test to Guide Primary Systemic Breast Cancer Chemotherapy

RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines

Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients

The RNA Disruption Assay is Superior to Conventional Drug Sensitivity Assays in Detecting Cytotoxic Drugs

Harnessing cell-free orphan non-coding RNAs as a predictive measure of long-term survival in neoadjuvant breast cancer therapy.

Reductions in Tumor RNA Integrity Associated with Clinical Response to Epirubicin/docetaxel Chemotherapy in Breast Cancer Patients.

RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced NSCLC Patients Treated with Cisplatin-Based Chemotherapy

Docetaxel‐induced Alterations in Cellular RNA in Ovarian Cancer Cells

RNA Disruption is a Widespread Phenomenon Associated with Stress-Induced Cell Death in Tumour Cells.

Mutational Landscape of Cfdna Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

A digital RNA signature of Circulating Tumor Cells predicting early therapeutic response in localized and metastatic breast cancer.

Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx).

Homologous recombination deficiency predicts response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: Secondary analysis of the neocart randomized clinical trial.

Predicting Treatment Outcome of Rectal Cancer Patients Underwent Neoadjuvant Chemoradiotherapy by Ctdna: the Potential Use of Ctdna Monitoring As Organ-Sparing Approach.

A RNA Signature Predicts Outcomes in Immune Checkpoint Blockade Treated Gastrointestinal Cancer Patients.

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.

Use of an RNA Interference Screen-Derived Mitotic and Ceramide Pathway Metagene to Predict Response to Paclitaxel Combination Chemotherapy in Primary Breast Cancer.

The analysis of transcriptomic signature of TNBC—searching for the potential RNA-based predictive biomarkers to determine the chemotherapy sensitivity

Association of extensive RNA disruption with natural killer cell-mediated death of K562 chronic myelogenous leukemia cells